Page 14 - Pharma

Lupin launches injectable iron formulation in India

The company has acquired exclusive marketing rights for this product from Danish firm Pharmacosmos

Evonik plans to buy Metabolic Explorer's methionine technology

The company has submitted a binding offer to takeover Metex's entire methionine technology platform including patents, essential bacteria strains and the inoLa brand

ICMR undertakes research initiative to eliminate TB from India

India TB Research and Development Corporation (ITRDC) to bring together all major national and international stakeholders to develop new tools (drug, diagnostics and vaccines) for TB

Biocon and Mylan submit application for biosimilar cancer drug trastuzumab in US

The application, which is believed to be the first for a proposed biosimilar trastuzumab in the US, marks first US regulatory submission through the Mylan-Biocon collaboration

Himachal Pradesh receives Centre's nod for pneumonia vaccine

HP will be among four other states (Bihar, UP, Rajasthan and Madhya Pradesh) that will introduce pneumonia vaccines under Universal Immunisation Programme from 2017

Biocompatibles pleads guilty to misbranding, agrees to pay $ 36 mn

The medical device maker, who has pleaded guilty to misbranding its embolic device LC Bead, will pay the amount to resolve criminal liability and False Claims Act allegations

Merck invests Euro 250 mn to expand pharma business' production in China

The investment will support Merck's expansion in China, which is expected to become the world's second-largest pharmaceutical market by 2018

European Medicines Agency accepts Mylan-Biocon's insulin glargine application

Glargine is one of the three insulin analogs being co-developed for the global marketplace by Mylan and Biocon - who are partners for a broad portfolio of biosimilars and insulin analogs

Wacker to expand pyrogenic silica production in Germany

The company will expand the specialty HDK pyrogenic silica plant at Burghausen (Germany), increasing the capacity of hydrophobic specialties by 40 percent

Is customisation the future of personal care industry?

Rising technological developments and product innovations are projected to be introduced in the next five years in countries such as China, India, Japan and South Korea, says Dr Mosongo Moukwa

Advanced Enzymes buys 70% stake in APIs maker JC Biotech

The acquisition will strengthen Advanced Enzymes' leadership position in API serratiopeptidase with 80% market share and also enables its foray into biopharma & algal DHA

Sun Pharma buys US-based Ocular Technologies for $ 40 million

The acquisition of Ocular Technologies, which is developing Seciera for the treatment of Dry Eye Disease, will enhance Sun Pharma's specialty ophthalmic pipeline

Dr Reddy's partners Gland Pharma in the US to market injectables

Through this alliance two companies are aiming to target a range of injectable products - the combined annual sale of which (branded as well as generics) is estimated at about $ 1 billion

Manjushree Technopack plans diversification to tap growing packaging market

With foray into shrink film packaging and plans to increase its presence pan India, the company aims to emerge as preferred packaging solution provider to various industries

Essel Propack's new tube making technology in US to raise productivity

While the currently equipped machines have capacity of 60 to 250 tubes per minute, the new SHOT line - installed at Danville (USA) facility - will produce 500 tubes per minute

Amgen invests in Israeli digital health incubator eHealth Ventures

Through this, Amgen aims to serve patients by driving innovation and sustainable healthcare through technology discovery

Indian Patent Office to create awareness programme for new IPR policy

The aim of the new policy is to provide IP protection in India to the innovator in a reasonable period of time without much problems, says O P Gupta, Controller General of Patents

The $ 240 bn biosimilar opportunity: Buddy up to succeed

Indian pharma companies will have to adopt strategy of collaboration (with global or domestic firms) to succeed in the market as cost of developing biosimilars are very high, says Pushpa Vijayraghavan

Glenmark receives US FDA's nod for antifungal cream

The company has received final approval for nystatin and triamcinolone acetonide cream (100,000 units per gm and 1 mg per gm)

Lanxess India inks pact to upgrade civil hospital's facilities in Nagda

As per the three-year agreement, the German specialty chemicals firm will contribute towards the upgradation of the existing facilities of the hospital